What is the 13F Pro Quality Score for HSIC?

13F Pro ranks HENRY SCHEIN INC (HSIC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HSIC's current score at https://13fpro.ai/research/HSIC (free sign-up required for the full ranking).

Where does 13F Pro source HSIC data?

All HENRY SCHEIN INC fundamentals and ownership data come directly from SEC EDGAR. HENRY SCHEIN INC files with the SEC under CIK 1000228. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HSIC in?

HENRY SCHEIN INC (HSIC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HSIC research updated on 13F Pro?

HSIC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HENRY SCHEIN INC(HSIC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1000228 HSIC stock profile & AI dashboard →

13F Pro Quality Score

52.0/100

Rank #1,368 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

41.4/100

Profitability

46.7/100

Balance Sheet

61.8/100

Earnings Quality

27.6/100

Free Cash Flow

36.4/100

Institutional Flow

15.9/100

Revenue Scale

89.1/100

Dilution Risk

82.6/100

HSIC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HENRY SCHEIN INC (HSIC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HSIC at 52.0/100 on a 32-signal composite quality model, placing it at rank #1,368 of 2,879 stocks — the top half of the AI-ranked universe. HSIC scores in the top quartile across revenue scale (89.1). Areas of concern include institutional flow (15.9) and earnings quality (27.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), HENRY SCHEIN INC reports quarterly revenue of $3.4B, net income of $107.0M, an operating margin of 5.4%. Top institutional holders of HSIC by reported 13-F value include Kohlberg Kravis Roberts & Co. L.P., BlackRock,, Artisan Partners Limited Partnership, based on the most recent SEC filings. HSIC trades on the Nasdaq exchange and files with the SEC under CIK 1000228. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HSIC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HENRY SCHEIN INC directly from SEC EDGAR. HENRY SCHEIN INC's 13F Pro composite quality score has ranged between 8 and 64 since 2021, currently 52.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about HENRY SCHEIN INC

Quirks, history, and lore behind HSIC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare distribution company · mid-cap · listed on Nasdaq · headquartered on Long Island, New York.
2
The Numbers
Annual revenue in the range of $12–13 billion, yet margins are thin — because the whole game is moving product efficiently to hundreds of thousands of small practices.
3
The History
Founded in 1932 as a small dental supply shop, it spent decades building one of the largest direct-to-practitioner distribution networks in healthcare.
4
The Secret
It doesn't just sell supplies — it also provides practice management software and technology solutions, making it sticky with the independent doctors and dentists it serves.
5
The Lore
It serves over one million healthcare practitioners across more than 30 countries, making it a quiet giant that keeps your dentist's drill stocked and their billing software humming.
6
The Giveaway
If your dentist, veterinarian, or doctor is in a small or mid-size practice, odds are high their dental chairs, syringes, and office software came from this Long Island distributor with a very distinguished-sounding name.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.4B

Net Income

Q1 2026

$107.0M

Free Cash Flow

Q1 2026

$-122.0M

Operating Margin

Q1 2026

5.4%

ROIC

Q1 2026

3.3%

D/E Ratio

Q1 2026

1.04

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.0% YoY

$13.18BFY 2025

FY21 $12.40BFY22 $12.65BFY24 $12.67BFY25 $13.18B

Net Income

+5.3% YoY

$419.0MFY 2025

FY21 $660.0MFY22 $538.0MFY24 $398.0MFY25 $419.0M

Operating Income

+5.2% YoY

$653.0MFY 2025

FY21 $852.0MFY22 $747.0MFY24 $621.0MFY25 $653.0M

EPS (Diluted)

+7.2% YoY

$3.27FY 2025

FY21 $4.45FY22 $3.91FY24 $3.05FY25 $3.27

Total Assets

+9.8% YoY

$11.21BFY 2025

FY21 $8.48BFY22 $8.61BFY24 $10.22BFY25 $11.21B

Total Debt

+22.5% YoY

$3.11BFY 2025

FY21 $884.0MFY22 $1.16BFY24 $2.54BFY25 $3.11B

Op. Cash Flow

-16.0% YoY

$712.0MFY 2025

FY21 $710.0MFY22 $602.0MFY24 $848.0MFY25 $712.0M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$13.18B +4.0%	$12.67B +0.2%	$12.65B +2.0%	$12.40B +22.6%	$10.12B -23.4%	$13.20B
Net Income	$419.0M +5.3%	$398.0M -26.0%	$538.0M -18.5%	$660.0M +63.4%	$404.0M -24.6%	$535.9M
Operating Income	$653.0M +5.2%	$621.0M -16.9%	$747.0M -12.3%	$852.0M +59.3%	$535.0M -10.9%	$600.6M
EPS (Diluted)	$3.27 +7.2%	$3.05 -22.0%	$3.91 -12.1%	$4.45 +57.8%	$2.82 -19.2%	$3.49
Total Assets	$11.21B +9.8%	$10.22B +18.7%	$8.61B +1.5%	$8.48B +9.1%	$7.77B -8.6%	$8.50B
Total Debt	$3.11B +22.5%	$2.54B +119.6%	$1.16B +30.7%	$884.0M +26.5%	$699.0M -64.0%	$1.94B
Operating Cash Flow	$712.0M -16.0%	$848.0M +40.9%	$602.0M -15.2%	$710.0M +18.5%	$599.0M -12.5%	$684.7M

AI Insight: HSIC Financial Trends

Revenue has grown steadily to $3,368M in Q1 2026, but debt has surged 36% from Q2 2024 levels while margins remain compressed and operating cash flow turned sharply negative.

• Revenue grew from $3,136M in Q2 2024 to $3,368M in Q1 2026, a modest but consistent upward trajectory over seven quarters.

• Operating income has oscillated between $151M and $182M with no clear expansion; Q1 2026's $182M is near the range high but barely above Q1 2025's $175M.

• Total debt climbed from $2,502M in Q2 2024 to $3,408M in Q1 2026, a 36% increase, while equity eroded from $3,512M to $3,266M over the same period.

• Operating cash flow turned sharply negative at -$97M in Q1 2026, the weakest reading across all eight quarters shown.

⚠ Debt-to-equity ratio has risen materially; at $3,408M debt vs. $3,266M equity in Q1 2026, leverage now exceeds 1x — a first in this dataset.

⚠ Net income has not recovered to Q2 2024 levels ($104M); Q2 2025's $86M trough signals potential margin or one-time cost pressure worth monitoring.

⚠ Operating cash flow volatility — swinging from $381M in Q4 2025 to -$97M in Q1 2026 — warrants scrutiny of working capital and seasonal dynamics.

AI Insight: HSIC Ratio Trends

Leverage has risen steadily to 1.04x D/E while returns and margins remain range-bound, signaling balance-sheet pressure without a clear earnings catalyst.

• D/E ratio expanded from 0.71 in Q2 2024 to 1.04 in Q1 2026, a 46% increase over seven quarters.

• Operating margin has stayed in a narrow 4.7%–5.5% band since Q2 2024, showing no durable expansion.

• ROIC slipped from 10.6% in Q2 2024 to 10.9% in Q1 2026, with a trough of 9.3% in Q2 2025 — limited recovery.

⚠ D/E crossed 1.0x for the first time in the dataset (Q1 2026); further borrowing could pressure interest coverage.

⚠ Q2 2025 was a clear soft patch — OpMargin 4.7%, ROE 10.0%, ROIC 9.3% — worth monitoring for recurrence.

⚠ Q1 seasonality consistently shows stronger margins (5.5% Q1 2025, 5.4% Q1 2026); sustainability into Q2 2026 is key.

Get alerted when HSIC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HENRY SCHEIN INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HSIC

Kohlberg Kravis Roberts & Co. L.P.
$1.2B15,652,032 sh
BlackRock, Inc.
$517.6M7,022,989 sh
Artisan Partners Limited Partnership
$484.4M6,573,023 sh
VANGUARD CAPITAL MANAGEMENT LLC
$473.4M6,423,167 sh
FMR LLC
$421.7M5,722,149 sh
Invesco Ltd.
$360.1M4,886,483 sh
STATE STREET CORP
$322.7M4,378,981 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$309.2M4,194,920 sh
AMERICAN CENTURY COMPANIES INC
$264.9M3,594,359 sh
Palestra Capital Management LLC
$251.5M3,412,667 sh

Fund	Value	Shares
Kohlberg Kravis Roberts & Co. L.P.	$1.2B	15,652,032
BlackRock, Inc.	$517.6M	7,022,989
Artisan Partners Limited Partnership	$484.4M	6,573,023
VANGUARD CAPITAL MANAGEMENT LLC	$473.4M	6,423,167
FMR LLC	$421.7M	5,722,149
Invesco Ltd.	$360.1M	4,886,483
STATE STREET CORP	$322.7M	4,378,981
VANGUARD PORTFOLIO MANAGEMENT LLC	$309.2M	4,194,920
AMERICAN CENTURY COMPANIES INC	$264.9M	3,594,359
Palestra Capital Management LLC	$251.5M	3,412,667

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HSIC on your watchlist

Track score changes the day HENRY SCHEIN INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HSIC a good stock to buy?

13F Pro's AI-powered analysis of HENRY SCHEIN INC (HSIC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HSIC are available on the HSIC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HSIC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HSIC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HENRY SCHEIN INC's investment landscape.